Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: silicified microcrystalline cellulose; croscarmellose sodium; magnesium stearate; maize starch - flecain is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecain should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecain tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: maize starch; magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; silicified microcrystalline cellulose; maize starch - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: citric acid monohydrate; colloidal anhydrous silica; stearic acid; purified talc; pregelatinised maize starch; microcrystalline cellulose; maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - fluoxetine mlabs is indicated for the treatment of:,major depression.,obsessive compulsive disorder.,premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - oral contraception

Australie - anglais - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - oral contraception

États-Unis - anglais - NLM (National Library of Medicine)

micro labs limited - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k), chlordiazepoxide (unii: 6rz6xez3cr) (chlordiazepoxide - unii:6rz6xez3cr) - chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. the therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. chlordiazepoxide and amitriptyline hydrochloride tablet is contraindicated in patients with hypersensitivity to either benzodiazepines or tricyclic antidepressants. it should not be given concomitantly with a monoamine oxidase inhibitor. hyperpyretic crises, severe convulsions and deaths have occurred in patients receiving a tricyclic antidepressant and a monoamine oxidase inhibitor simultaneously. when it is desired to replace a monoamine oxidase inhibito

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -